At the news
? BULLISHIMPACT 5/10 8-K filed Jun 2, 2026 at 15:35 ET
PDS Biotechnology Corp received a Nasdaq notice on June 2, 2026 confirming it has regained compliance with the $1.00 minimum bid price requirement, closing the deficiency matter first disclosed on February 25, 2026. This removes the immediate delisting risk from Nasdaq, a positive administrative outcome for the $64M market cap clinical-stage biotech.
- On February 25, 2026, PDSB received a Nasdaq deficiency letter for trading below $1.00 for 30 consecutive business days.
- On June 2, 2026, Nasdaq notified PDSB that it has regained compliance with the minimum bid price requirement and closed the matter.
- The company's common stock continues to trade on The Nasdaq Capital Market under the symbol PDSB.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access